蜂毒注射液对类风湿关节炎成纤维样滑膜细胞Bax、Bcl-2的影响  

Effect of Apistoxin Injection on Bax and Bcl-2 expression in fibroblast-like synoviocytes of rheumatoid arthritis

作　　者：罗晓光[1] 张洁瑶[1] 黎德育[1] LUO Xiao-guang;ZHANG Jie-yao;LI De-yu(Shenzhen Union Hospital of Huazhong University of Science and Technology,Shenzhen 518052,China)

机构地区：[1]华中科技大学协和深圳医院,广东深圳518052

出　　处：《现代药物与临床》2020年第2期202-205,共4页Drugs & Clinic

基　　金：深圳市南山区技术研发和创意设计项目(2014046)。

摘　　要：目的观察蜂毒注射液对人类风湿关节炎成纤维样滑膜细胞(类风湿关节炎-FLS)B淋巴细胞瘤-2基因(Bcl-2)、Bcl-2相关X蛋白(Bax)m RNA和蛋白的影响,探讨蜂毒注射液治疗类风湿关节炎的作用机制。方法滑膜组织取自行关节置换或关节镜手术的4名活动期类风湿关节炎患者,分离出FLS并原代培养,逆转录–聚合酶链反应(RT-PCR)观察Bax、Bcl-2 mRNA表达的变化,酶联免疫吸附测定(ELISA)法检测Bax、Bcl-2蛋白水平的变化。结果与对照组比较,蜂毒注射液4、8、16 mg/L组能促进Bax mRNA表达(P<0.05),蜂毒注射液8、16 mg/L组抑制Bcl-2 mRNA表达(P<0.05、0.01);蜂毒注射液4、8、16 mg/L组提高Bax蛋白水平,降低Bcl-2蛋白水平(P<0.05、0.01),且有一定的剂量相关性。结论蜂毒注射液可能通过抑制Bcl-2蛋白、促进Bax蛋白的表达,达到促进类风湿关节炎-FLS凋亡的作用。Objective To observe the effect of Apistoxin Injection on B-lymphoma-2 gene(Bcl-2), Bcl-2-related X protein(Bax) m RNA and protein in human rheumatoid arthritis fibroblast like synoviocytes(RA-FLS), and to explore the mechanism of Apistoxin Injection in treatment of rheumatoid arthritis. Methods FLS was isolated from synovium of 4 active RA patients who underwent arthroscopic surgery or joint replacement. The expression of Bax and Bcl-2 mRNA was observed by Real time-PCR(RT-PCR) method, and the contents of Bax and Bcl-2 protein were detected by ELISA method. Results Compared with the control group, Apistoxin Injection 4, 8, and 16 mg/L groups could promote the expression of Bax mRNA(P<0.05), and Apistoxin Injection 8 and 16 mg/L groups could inhibit the expression of Bcl-2 mRNA(P<0.05, 0.01). Apistoxin Injection 4, 8, and 16 mg/L groups could increase the content of Bax protein and decrease the content of Bcl-2 protein(P<0.05, 0.01), which was dose-dependent. Conclusion Apistoxin injection may promote the apoptosis of RA-FLS by inhibiting the expression of Bcl-2 protein and promoting the expression of Bax protein.

关 键 词：蜂毒注射液 类风湿关节炎 成纤维样滑膜细胞 B淋巴细胞瘤-2基因 Bcl-2相关X蛋白 

分 类 号：R966[医药卫生—药理学]